Dtsch Med Wochenschr 2011; 136(48): 2489-2491
DOI: 10.1055/s-0031-1297274
Rheumatologie | Commentary
Rheumatologie, Stoffwechselerkrankungen
© Georg Thieme Verlag KG Stuttgart · New York

Hyperurikämie, Gicht, Pseudogicht und Begleiterkrankungen

Hyperuricemia, gout, pseudogout and concomitant diseasesB. M. W. Schmidt1 , A. D. Wagner1
  • 1Klinik für Nieren- und Hochdruckerkrankungen, Medizinische Hochschule Hannover
Further Information

Publication History

Publication Date:
22 November 2011 (online)

   Permissions and Reprints
Preview

Schlüsselwörter

Gicht - Pseudogicht - Hyperurikämie - Febuxostat - Canakinumab

Keywords

gout - pseudogout - hyperuricemia - febuxostat - caanakinumab

Literatur

  • 1 Bhole V, Choi J W, Kim S W, de Vera M, Choi H. Serum uric acid levels and the risk of type 2 diabetes.  Am J Med. 2010;  123 957-961
    Search in Google Scholar
  • 2 Filippatos G S, Ahmed M I, Gladden J D. et al . Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data.  Eur Heart J. 2011;  32 712-720
    Search in Google Scholar
  • 3 Fravel M A, Ernst M E. Management of gout in the older adult.  Am J Geriatr Pharmacother. 2011;  9 271-285
    Search in Google Scholar
  • 4 Goicoechea M, de Vinuesa S G, Verdalles U. et al . Effect of allopurinol in chronic kidney disease progression and cardiovascular risk.  Clin J Am Soc Nephrol. 2010;  5 1388-1393
    Search in Google Scholar
  • 5 Kao M P, Ang D S. et al . Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease.  J Am Soc Nephrol. 2011;  22 1382-1389
    Search in Google Scholar
  • 6 Kielstein J T, Schmidt B MW. High-dose allopurinol in patients with stable angina pectoris.  Lancet. 2010;  376 1298-1299
    Search in Google Scholar
  • 7 Martin W J, Walton M, Harper J. Resident macrophages initiating and driving inflammation in a monosodium urate monohydrate crystal-induced murin peritoneal model of acute gout.  Arthritis Rheum. 2009;  60 281-289
    Search in Google Scholar
  • 8 Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout associated uric acid crystals activate the NALP3 inflammasome.  Nature. 2006;  440 237-241
    Search in Google Scholar
  • 9 Richette P, Ottaviani S, Bardin T. New therapeutic options for gout.  Presse Med. 2011;  40 844-849
    Search in Google Scholar
  • 10 Schlesinger N, Mysler E, Lin H -Y. et al . Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment.  Ann Rheum Dis. 2011;  70 1264-1271
    Search in Google Scholar
  • 11 So A, De Meulemeester M, Pikhlak A, Yücel A E, Richard D, Murphy V, Sallstig P, Schlesinger N. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis.  Arthritis Rheum. 2010;  62 3064-3076
    Search in Google Scholar
  • 12 Wen C P, David C heng TY, Chan H T. et al . Is high serum uric acid a risk marker or a target for treatment?.  Am J Kidney Dis. 2010;  56 273-288
    Search in Google Scholar
  • 13 Whelton A, Macdonald P A, Zhao L, Hunt B, Gunawardhana L. Renal function in gout: long-term treatment effects of febuxostat.  J Clin Rheumatol. 2011;  17 7-13
    Search in Google Scholar
  • 14 Zhang W, Doherty M, Bardin T. et al . EULAR evidence based recommendations for gout. Part II: Management.  Ann Rheum Dis. 2006;  65:1 312-324
    Search in Google Scholar

PD Dr. med. Annette D. Wagner

Oberärztin, Vaskulitisambulanz Spezialambulanz „Seltene entzündliche Systemerkrankungen mit Nierenbeteiligung“,
Klinik für Nieren- und Hochdruckerkrankungen
Medizinische Hochschule Hannover

Carl-Neuberg-Str. 1

30625 Hannover

Phone: 0511/532-3745

Fax: 0511/532-8108